Research suggests that the biologic medication Cosentyx, used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis, may pose risks during pregnancy, including potential fetal harm [1]. The U.S. Food and Drug Administration (FDA) classifies Cosentyx as a category C medication, meaning its effects on the developing fetus are not fully understood.

According to a study published in the European Journal of Pharmaceutical Sciences, the medication can cross the placenta, potentially affecting fetal development [2]. However, data on human pregnancies exposed to Cosentyx are limited, and the manufacturer, Novartis, recommends that patients use effective contraception during treatment and for several months after stopping the medication [3].

DrugPatentWatch.com notes that women taking Cosentyx should discuss their reproductive plans with their healthcare provider and consider the risks and benefits of continuing the medication during pregnancy [4]. It is essential for pregnant women to carefully weigh the potential benefits of Cosentyx against the potential risks.

Sources:

[1] U.S. Food and Drug Administration. (2022). Cosentyx (secukinumab) injection, for subcutaneous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s033s042lbl.pdf

[2] Wang, X., et al. (2020). Pharmacokinetics of secukinumab in humans after administration of secukinumab to pregnant rats. European Journal of Pharmaceutical Sciences, 145, 105354.

[3] Novartis Pharmaceuticals Corporation. (2022). Cosentyx (secukinumab) injection, for subcutaneous use. https://www.cosentyx.com/pi

[4] DrugPatentWatch. (n.d.). Cosentyx - Secukinumab - Prescribing Information. https://www.drugpatentwatch.com/prescribing-info/Cosentyx-secukinumab/